These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1300 related items for PubMed ID: 7911399

  • 21. [Lansoprazol].
    Ponce J, Nos P.
    Gastroenterol Hepatol; 1995 Feb; 18(2):101-9. PubMed ID: 7621274
    [No Abstract] [Full Text] [Related]

  • 22. Pharmacotherapy for acid/peptic disorders.
    Schubert ML.
    Yale J Biol Med; 1996 Feb; 69(2):197-201. PubMed ID: 9112751
    [Abstract] [Full Text] [Related]

  • 23. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
    Spencer CM, Faulds D.
    Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
    [Abstract] [Full Text] [Related]

  • 24. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
    Goldstein JL, Huang B, Amer F, Christopoulos NG.
    Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
    [Abstract] [Full Text] [Related]

  • 25. The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients.
    Jhala NC, McFarland MM, Brightman SA, Morale B, Rubin W, Atkinson BF.
    Am J Gastroenterol; 1995 Oct; 90(10):1824-8. PubMed ID: 7572902
    [Abstract] [Full Text] [Related]

  • 26. Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
    Russo A, Dattilo M.
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):312-9. PubMed ID: 9476183
    [Abstract] [Full Text] [Related]

  • 27. Effect of lansoprazole on peptic ulcers.
    Ohashi T, Sakata J, Haraguchi Y, Eto T.
    J Clin Gastroenterol; 1995 Aug; 20 Suppl 2():S83-5. PubMed ID: 7594350
    [Abstract] [Full Text] [Related]

  • 28. An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
    Bown RL.
    Int J Clin Pract; 2002 Mar; 56(2):132-9. PubMed ID: 11926700
    [Abstract] [Full Text] [Related]

  • 29. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
    Adachi K, Hashimoto T, Komazawa Y, Mihara T, Furuta K, Fujishiro H, Ishihara S, Amano Y, Hattori S, Kinoshita Y.
    Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
    [Abstract] [Full Text] [Related]

  • 30. Continuous maintenance with low-dose lansoprazole versus Helicobacter pylori eradication in the prevention of duodenal ulcer recurrence.
    Parente F, Bargiggia S, Bollani S, Colombo E, Bianchi Porro G.
    Hepatogastroenterology; 1998 Jul; 45(22):990-3. PubMed ID: 9755995
    [Abstract] [Full Text] [Related]

  • 31. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A, Celikel CA, Ozdogan O, Tözün N, Ulusoy NB, Kalayci C.
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [Abstract] [Full Text] [Related]

  • 32. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI.
    Ohara T, Morishita T, Suzuki H, Masaoka T, Ishii H.
    Hepatogastroenterology; 2004 Dec; 51(56):338-42. PubMed ID: 15086153
    [Abstract] [Full Text] [Related]

  • 33. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
    Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Robinson M, McFarland M, Sabesin S, Lehman GA, Castell D.
    Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
    [Abstract] [Full Text] [Related]

  • 34. [Lansoprazol ++ : a new proton pump inhibitor].
    Baczek J, Laskowiec G.
    Pol Merkur Lekarski; 1998 Jun; 4(24):339-41. PubMed ID: 9771021
    [Abstract] [Full Text] [Related]

  • 35. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
    Gremse DA.
    Expert Opin Pharmacother; 2001 Oct; 2(10):1663-70. PubMed ID: 11825309
    [Abstract] [Full Text] [Related]

  • 36. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer.
    Lazzaroni M, Bargiggia S, Bianchi Porro G.
    Am J Gastroenterol; 1997 Apr; 92(4):649-52. PubMed ID: 9128316
    [Abstract] [Full Text] [Related]

  • 37. Long-term management of gastroesophageal reflux disease and its complications.
    Richter JE.
    Am J Gastroenterol; 1997 Apr; 92(4 Suppl):30S-34S; discussion 34S-35S. PubMed ID: 9127624
    [Abstract] [Full Text] [Related]

  • 38. Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers.
    Arkkila PE, Seppälä K, Kosunen TU, Sipponen P, Mäkinen J, Rautelin H, Färkkilä M.
    Eur J Gastroenterol Hepatol; 2005 Jan; 17(1):93-101. PubMed ID: 15647648
    [Abstract] [Full Text] [Related]

  • 39. Eradication of H. pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study.
    Gupta VK, Dhar A, Srinivasan S, Rattan A, Sharma MP.
    Am J Gastroenterol; 1997 Jul; 92(7):1140-2. PubMed ID: 9219786
    [Abstract] [Full Text] [Related]

  • 40. Clinical review of lansoprazole.
    Lockhart SP.
    Br J Clin Pract Suppl; 1994 Jul; 75():48-55; discussion 56-7. PubMed ID: 8060802
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 65.